CTLA4-Ig

CTLA4-Ig

A fusion protein specific for the B7 surface receptor on T cells that has been shown to be capable of persuading T cells to recognize severely mismatched allogeneic transplanted organs as ‘self’ even in the absence of immunosuppressive drugs. T cell activation requires two signals—a T cell-receptor-mediated signal and a co-stimulatory signal. Co-stimulation involves the B7 receptor. This fusion protein blocks co-stimulation and prevents T cells from mounting a rejection attack.
References in periodicals archive ?
CTLA4-Ig fusion proteins contain the extracellular domain of CTLA-4 and Fc fragment of human IgG antibody.
Also in Maxygen's pipeline are a new Factor VIIa product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis.
CTLA4-Ig belongs to a new class of therapeutic agents known as costimulation blockers.
The two that received only CTLA4-Ig rejected the new organ within a month.
Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic (designated as ASP2408) that is being developed by Perseid Therapeutics LLC, Maxygen's majority-owned subsidiary, in collaboration with Astellas Pharma Inc.
Separately, Repligen announced that is has received a Notice of Allowance from the United States Patent and Trademark Office on a patent which claims the use of CTLA4-Ig for treatment of rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosis.
to co-develop and commercialize next-generation CTLA4-Ig therapeutics.
Repligen Corporation (Needham, MA; 781-449-9560) announced that it has acquired rights to a United States patent application broadly claiming the use of CTLA4-Ig in immune-based diseases and organ transplantation.
under which the company and Astellas are exploring new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis, transplantation rejection and other autoimmune disorders.
under which the company and Astellas are exploring new CTLA4-Ig product candidates for the treatment of a broad array of autoimmune disorders and transplantation rejection.
Maxygen also has a MAXY-4 program, partnered with Astellas Pharma, under which the companies are exploring new CTLA4-Ig product candidates for the treatment of autoimmune disorders, including rheumatoid arthritis, and transplant rejection.